Mark Breidenbach
Stock Analyst at Oppenheimer
(1.28)
# 3,690
Out of 5,117 analysts
52
Total ratings
30.91%
Success rate
-0.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.38 | +407.25% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $19.30 | +55.44% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $12.16 | +681.25% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $6.73 | +271.47% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.32 | +2,978.82% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $14.65 | +1,538.23% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.90 | +5,417.24% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.54 | +354.55% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.70 | +1,782.35% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $2.85 | +426.32% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.22 | +9,736.07% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.02 | +955,782.35% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.38
Upside: +407.25%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $19.30
Upside: +55.44%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $12.16
Upside: +681.25%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $6.73
Upside: +271.47%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.32
Upside: +2,978.82%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $14.65
Upside: +1,538.23%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.90
Upside: +5,417.24%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.54
Upside: +354.55%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.70
Upside: +1,782.35%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.85
Upside: +426.32%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.22
Upside: +9,736.07%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.02
Upside: +955,782.35%